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To estimate the risk of venous thrombosis associated with pancreatic malignancies we fol-
lowed a cohort of patients with pancreatic cancer (n = 202). We calculated incidence rates of
venous thrombosis and compared this with population rates using a Standardised Morbid-
ity Ratio (SMR). The effects of location, histology and treatment were assessed by Cox-
modelling. The incidence of venous thrombosis was 108.3/1000 patient-years (95%
confidence interval (CI) 64.4–163.8), 58.6-fold increased (SMR 58.6, 95% CI 36.9–92.9).
Patients with a tumour of the corpus/cauda had a 2-fold increased risk compared with
those with a tumour of the caput. Patients treated with chemotherapy had a 4.8-fold
increased risk (HRadj 4.8, 95% CI 1.1–20.8), whereas radiotherapy did not increase the risk.
In a postoperative period of 30 d, patients had a 4.5-fold increased risk of venous thrombo-
sis (HRadj 4.5, 95% CI 0.5–40.9). The risk was 1.9-fold increased in the presence of distant
metastases (HRadj 1.9, 95% CI 0.7–5.1). Anti-thrombotic prophylaxis seems warranted in
the first month after surgery, during and after treatment with chemotherapy, and when
distant metastases have been diagnosed.
 2005 Elsevier Ltd. All rights reserved.1. Introduction
Tumours of the pancreas are known to be associated with a
high incidence of venous thrombosis. Sproul and colleagues
conducted the first study reporting the relationship between
pancreatic tumours and venous thrombosis in 1938 [1]. They
described autopsy reports and found 60% (28 out of 47) of pa-
tients with pancreatic cancer had venous thrombosis in vari-
ous locations, compared with 15–25% of patients with other
malignancies. She concluded that pancreatic cancer often
leads to venous thrombosis. Since this report, other studies
have confirmed a correlation between pancreas carcinoma
and venous thrombosis [2–4]. A high risk of venous thrombo-
sis in patients with pancreatic cancer may result from the re-er Ltd. All rights reserved
; fax: +31 070 5266994.
.R. Rosendaal).lease of prothrombotic factors by the tumour, such as trypsin
or mucin [5].
The relationship between pancreatic carcinoma and ve-
nous thrombosis is not unique. Lung cancer, prostate cancer,
colon cancer and haematological cancer as well as pancre-
atic cancer are all associated with thrombosis, and are more
often found in patients with idiopathic venous thrombosis
than secondary venous thrombosis [6]. However, the inci-
dence of symptomatic deep venous thrombosis and pulmon-
ary embolism in patients with pancreatic cancer has not
been measured accurately. For clinical practice an assess-
ment of the magnitude of risk is important and, specifically,
of the absolute risk, which is the basis of strategies for
thromboprophylaxis..
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venous thrombosis for patients with pancreatic cancer, and
assess the effect of localisation, histological characteristics
and treatment. We also compared the incidence of venous
thrombosis with general population data.
2. Patients and methods
2.1. Patient selection
Between January 1990 andDecember 2000, 252 consecutive pa-
tients were admitted to the Leiden University Medical Centre
(LUMC)with a tumour of the pancreas. Patientswere identified
from the oncology registration database of the hospital. This
databasewas set up in 1970 and is staffed by specialised oncol-
ogy data managers. It includes information on all patients
diagnosed with and admitted for cancer in the LUMC. We ex-
cluded 27 patients because they only briefly visited the LUMC
for diagnosis or therapy and 7 patients because they had a
diagnosis of pancreatic cancer before 1990 or a primary diag-
nosis of pancreatic cancer that could not be confirmed. Six-
teen medical records could not be traced. For the analysis we
included 202 patients with a first diagnosis of pancreatic can-
cer established in the LUMC or with a first diagnosis within
2 months before referral to the LUMC. There were 115 men
and 87 women in this patient group. Eighteen patients had a
previous malignancy in their medical history, and for 2 of
these it was unclearwhether the pancreatic tumourwashisto-
logically different from the other malignancy.
2.2. Data collection
From the medical records, clinical characteristics, such as
demographic data, use of anticoagulants, treatment (surgery,
radiotherapy, chemotherapy) were recorded. In addition, tu-
mour characteristics (the histological or cytological classifica-
tion of the tumour, localisation and the extent of disease) were
recorded. Thrombotic events, defined as deep venous throm-
bosis of the leg or arm or a pulmonary embolism after the first
diagnosis of pancreatic cancer, were identified through the re-
gional Anticoagulation Clinics. In the Netherlands, the antico-
agulation clinicsmonitor all patients receiving treatment with
oral anticoagulant therapy.We ascertained the occurrence of a
venous thrombotic event since diagnosis of cancer from the
records of the regional Anticoagulation Clinic and by consult-
ing general practitioners.
Information on the date of death was obtained from the
medical records, the registration offices of the municipalities
where the patients lived or from their general practitioner. No
information was available for 1 patient at the anticoagulation
clinic or general practitioner, whereas the date of death was
known. This resulted in a loss of a maximum of 0.4 person
years.
2.3. Diagnosis
For 144 patients the diagnosis of pancreatic cancer was based
on histological (n = 102) or cytological (n = 42) examination. In
the 58 remaining cases, diagnosis was based on ultrasound or
computer tomography imaging inaddition toclinical symptoms.2.4. Stage of disease
We used two stages for the classification of the extent of dis-
ease using the TNM-classification system. T indicates the size
of the tumour, N indicates lymph node spread and M indi-
cates the presence or absence of distant metastases. Any T,
any N, M0 was classified as local tumour growth with or with-
out lymph node spread and no distant metastases. The sec-
ond group comprised patients with distant metastases (any
T, any N, M+). In 14 cases, staging was not performed at diag-
nosis due to lack of therapeutic consequences. For the same
reason, during the course of disease, the search for distant
metastases was not always completed.
2.5. Therapy
Patients without distant metastases at diagnosis could be
classified according to four different therapeutic approaches
(Table 1):
• no further therapy;
• major surgery (pancreas tumour resection);
• explorative or palliative surgery (i.e., biliodigestive anasto-
mosis or placing of stent);
• surgery with a combination of 5 weeks of radiotherapy and
5-fluorouracil in the first and fifth week of the radiotherapy
(RT/5-FU). This therapy was given to patients who had a
residual tumour mass of less than 5 cm after surgical
therapy.
Patients with distant metastases at diagnosis were cate-
gorised as those without further surgical therapy and patients
with explorative or palliative therapy (Table 1).
Radiotherapy was always given on the primary tumour
area.
2.6. Statistical analysis
For each subject, person-years of follow-up were counted
from the date of first contact until the date of a thrombotic
event, the date of death, or the end of the study period (31st
December 2000), whichever occurred first. A total of 176 per-
son-years accrued. By dividing the number of cases of deep
venous thrombosis or pulmonary embolism by the number
of person-years we computed the incidence rates. An age-
and sex-adjusted relative risk (Standardised Morbidity Ratio
(SMR)) of venous thrombosis compared with the general pop-
ulation was calculated by comparing the observed sum of ve-
nous thrombotic events with the expected sum of events
using the age- and sex-specific incidence rates of venous
thrombosis of the leg and pulmonary embolism from the
Dutch general population [7].
The effect of various factors on the occurrence of throm-
bosis was estimated by Cox proportional hazards models in
which the hazard ratio can be seen as a relative risk. A time-
dependent covariate for distant metastases (m) was added to
the Cox-regressionmodel,withm = 0whennodistantmetasta-
ses were present and m = 1 from the moment distant metasta-
ses were diagnosed. For therapy we also used time-dependent
covariates,with avariable t for chemotherapy.With t = 1 as ever
Table 1 – Stage of disease and therapeutic approaches
Distant metastases
at diagnosis
Initial treatment (IT) Median
survival
(years)
Venous
thrombosis
after IT (n)
Second
treatment
(ST)
Venous
thrombosis
after ST (n)
Absent (n = 81) Major surgery, no residual
tumour left (n = 21)
2.3 2a 1 RT
1 CT + RT
Surgery, (2 major, 20 explorative/palliative)
residual tumour 65 cm left (n = 22)
1.2 RT/5-FU 1
Explorativec or palliatived surgery, primary
tumour still in situ (n = 23)
0.7 2b 1 CT + RT 1
1 RT
No further therapy (n = 15) 0.3 0
Present (n = 107) Explorative or palliative
surgery (n = 40)
0.5 3 6 CT 2
3 RT/5-FU
No further surgery (n = 67) 0.3 8 4 CT
3 RT
Not determined (n = 14) 3 palliative surgery 0.5 0
11 no further therapy
CT, chemotherapy; RT, radiotherapy; 5-FU, 5-fluorouracil.
a 1 venous thrombosis in post-operative phase, 1 venous thrombosis before surgery.
b 1 venous thrombosis in postoperative phase.
c Only biopsy has been taken.
d Biliodigestive anastomosis.
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therapy started, and t = 0 as never having received chemother-
apy or not yet having received chemotherapy. Similarly, for
patients receiving radiotherapy (alone or in combination with
5-fluorouracil), with variable r defined as r = 1 as ever having
received radiotherapy starting from the moment the therapy
started, and r = 0 as never having received radiotherapy or not
yet having received radiotherapy. Surgery plus 1 month post-
operative also was a time-dependent covariate. This period of
1 monthwas chosen arbitrarily. Explorative operation or pallia-
tive surgery was not regarded as surgery in thismodel, because
of its minor size compared with surgery for pancreas tumour
resection. In the regression model we adjusted for age, sex
and other possibly confounding variables.
3. Results
In this cohort of 202 patients the mean age at diagnosis was
64 years, with a median survival of 0.5 years from diagnosis
until the end of the study or death. Twelve patients suffered
from deep venous thrombosis of the leg, 4 patients had a pul-
monary embolism and 2 patients had both. One patient devel-
oped arm thrombosis while having a central venous catheter.
Six patients had a venous thrombosis in their medical history
prior to cancer diagnosis. One of them had the thrombosis 1
month before the diagnosis of pancreatic cancer. The other
5 patients had venous thrombosis 4–19 years before the diag-
nosis of pancreatic cancer. None of the patients with a history
of venous thrombosis had a venous thrombotic event after
the diagnosis of pancreatic cancer. Eight patients used oral
anticoagulant therapy for more than 2 months during the fol-
low-up period for reasons other than venous thrombosis.
None of these patients developed a venous thrombosis after
the diagnosis of pancreatic cancer.
We observed 19 cases of venous thrombosis during the fol-
low-up period, with an incidence rate of 108.3/1000 patient-years, 95% CI 64.4–163.8 (overall cumulative incidence 94.1/
1000, 95% CI 90.9–97.3). Fifteen out of 19 cases of venous
thrombosis occurred in the first 6 months since diagnosis of
the tumour (cumulative incidence 74.3/1000 (68.3–80.3)), 3
cases between 6 and 12 months, whereas 1 case occurred 4
years after diagnosis of the tumour. In the first 3 months fol-
lowing the diagnosis of cancer the incidence rate was 207.0/
1000 patient-years (95% CI 92.0–367.8), and in the following 3
months it decreased to 91.9/1000 patient-years (95% CI 34.5–
187.6). From 6 months until 1 year after cancer diagnosis the
incidence rate was 34.7/1000 patient-years (95% CI 6.2–86.3).
Based on sex- and age-specific rates of venous thrombosis
in the general population [7], only 0.31 cases of deep venous
thrombosis of the leg or pulmonary embolism were expected.
The 19 cases that were observed resulted in a 58-fold in-
creased risk compared with the general population (SMR
58.6, 95% CI 36.9–92.9).
The localisation of the tumour in the pancreas could be
determined in 194 cases. Tumours were most often located
in the caput (n = 149), 21 tumours were located in the corpus
and 23 in the cauda. One tumour was located in the peri-
ampullary area. Tumours located in the corpus and cauda of
the pancreas had a 2–3-fold increased risk of venous thrombo-
sis compared with tumours in the caput of the pancreas (HR
1.9, 95% CI 0.5–6.7, and HR 2.9, 95% CI 1.0–8.5, respectively).
Although tumours in the corpus and cauda were more often
associated with distant metastases at diagnosis (70% versus
47%), after adjusting for distant metastasis, age and sex, these
tumours still had an increased risk of venous thrombosis (HR
1.6, 95% CI 0.4–5.9 and HR 2.5, 95% CI 0.9–7.4, respectively). Of
the 102 patients with a histological diagnosis, 41 had a mucin-
ous adenocarcinoma and 47 a non-mucinous adenocarci-
noma. Seven patients had a neuro-endocrine carcinoma
and 7 were classified as other tumour type. The distribution
of the histological types of tumour was different between
the various localisations. In the group of patients with a
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adenocarcinoma in the corpus and cauda more often than in
the caput of the pancreas (48% versus 37%). We found no dif-
ference in risk of venous thrombosis in mucinous adenocarci-
noma compared with non-mucinous adenocarcinoma (HRadj
1.0, 95% CI 0.2–4.6), adjusted for distant metastasis, age and
sex.
A total of 107 patients (53%) had distant metastases at the
time of diagnosis and another 23 (11%) were diagnosed with
distant metastases in the follow-up period. For patients with
distant metastases the risk of venous thrombosis was 2-fold
increased (HRadj 1.9, 95% CI 0.7–5.1, adjusted for age, sex, sur-
gery and chemo- or radiotherapy) (Fig. 1). The cumulative
incidence of venous thrombosis after detection of distant
metastases was 87.3/1000 persons/6 months (95% CI 38.0–
136.6). The incidence of venous thrombosis was 50.0/1000 per-
sons/6 months (95% CI 2.2–97.8) in the absence of distant
metastases.
Eleven out of 19 patients with a venous thrombosis died
within 1 month after the venous thrombosis. These were pa-
tients who also had distant metastases at diagnosis. The
median time for patients with distant metastasis to develop
venous thrombosis was 92 d. Median survival after cancer
diagnosis of patients with a venous thrombosis and distant
metastases was 104 d. Patients with distant metastases who
did not develop a venous thrombosis had a median survival
of 116 d.
Twenty-three out of 81 patients without distant metasta-
ses had major surgery and 43 out of 81 had minor surgery
(Table 1). Among 107 patients with distant metastases 40
had minor surgery. Three of the 14 patients in whom stag-
ing of the disease was not performed had minor surgery.
One patient developed a pulmonary embolism within 2
weeks after major surgery resulting in a 4-fold increasedTime since metastases (years)
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Fig. 1 – Risk of venous thrombosis in the presence of distant
metastases compared with no distant metastases.risk (HRadj 4.5, 95% CI 0.5–40.9) for patients in the postoper-
ative period of 30 d.
Twenty-six out of 81 patients without distant metastases
received radiotherapy after surgery (Table 1); 22 had radio-
therapy in combination with 5-FU and 2 had radiotherapy
as well as other forms of chemotherapy. Six out of 107 pa-
tients with distant metastases received radiotherapy (3 in
combination with 5-FU) and 10 of these 107 received chemo-
therapy. Radiotherapy with 5-FU was usually given shortly
after surgery, while other forms of chemotherapy or radio-
therapy were given 1–52 weeks after surgery. Two patients
with a neuro-endocrine carcinoma had chemotherapy also
before surgery. Chemotherapy was mostly given to patients
with distant metastases (Table 1). No increased risk was
found for patients after receiving radiotherapy (HRadj 0.5,
95% CI 0.1–3.9, adjusted for age, sex and distant metastases).
Three patients developed deep venous thrombosis of the leg
within 3 months after discontinuation of their chemotherapy.
We found a 4.8-fold increased risk for patients after receiving
chemotherapy (HRadj 4.8, 95% CI 1.1–20.8, adjusted for age, sex
and distant metastases).
4. Discussion
This cohort study of patients with a first diagnosis of pancreas
carcinoma shows that the risk of venous thrombosis is 60-
fold increased compared with the general population, at a
cumulative risk of nearly 10%. Cumulative incidence in the
first half year since diagnosis of cancer was 74.3/1000 per-
sons/6 months (95% CI 68.3–80.3), compared with the 39.1/
1000 persons/6 months (95% CI 22.7–55.5) found earlier for
lung cancer patients [8].
Patients with pancreatic cancer have always been as-
sumed to have the highest incidence of venous thrombosis
compared with patients with other cancers. This assumption
began with the publication of a post-mortem study in 1938
[1]. However, in this report the localisation of the thrombosis
was not stated and the conclusions were based on a rela-
tively small number of patients with pancreatic cancer
(n = 47). Since this study the relationship between pancreatic
cancer and thrombotic events has been reviewed extensively
and incidences varying from 5% to 60% have been found [2].
Many studies, however, included thrombi in veins contigu-
ous with the tumour comprising about one-third of the
thrombi found in these patients [2]. In agreement with our
findings of 2 (1%) of 202 patients who died due to pulmonary
embolism, others found 4 out of 541 (0.7%) cases with fatal
pulmonary embolism [9].
In agreement with other studies of patients with pancreas
tumours, we found that tumours of the corpus and cauda of
the pancreas are associated with a higher incidence of venous
thrombosis than tumours of the caput of the pancreas
[1,2,5,10]. In our cohort, tumours of the corpus and cauda
were more often mucinous adenocarcinomas, which might
explain this higher incidence. Another reason for a higher
incidence of venous thrombosis could be a larger tumour
load. Tumours of the corpus and cauda are more often de-
tected at a later stage due to the lack of symptoms and thus
already have a larger volume than tumours of the caput of
the pancreas [11].
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at the moment of diagnosis of the pancreas tumour. We saw a
clear increase in the risk of venous thrombosis in the pres-
ence of distant metastasis.
In our study, there was a 4.8-fold increased risk of ve-
nous thrombosis after patients had been treated with che-
motherapy. Surgery increased the risk 4-fold. The risk of
venous thrombosis has previously been shown to be higher
in cancer patients who receive chemotherapy [8,12,13] com-
pared with those without chemotherapy. In addition, an in-
crease in risk has been described before for radiotherapy
[14] and surgery [15], but in our study there was no
increase in risk during or after being treated with
radiotherapy.
The underlying condition of the patient (e.g., immobilisa-
tion) could cause an overestimation of the effect of therapy
or the presence of distant metastases on the risk of venous
thrombosis. We limited this effect by including therapy and
distant metastases as time-dependent variables in the Cox-
model, so the effects of these variables are measured within
the same individual and therefore the underlying condition
of the patient in all likelihood would not alter the hazard
ratio.
4.1. Clinical consequences
Only two patients with distant metastases died directly after a
venous thrombotic event. It is unlikely that prophylactic anti-
coagulant treatment preventing venous thrombotic events
would result in a gain in life expectancy for patients who al-
ready have distant metastasis. However, for patients with dis-
tant metastases prophylactic anticoagulant treatment may
prevent serious co-morbidity and associated suffering. The
incidence of bleeding so far described for cancer patients
receiving anticoagulant treatment [16,17] is markedly lower
than the incidence of venous thrombosis in patients with dis-
tant metastases.
For patients without distant metastasis, the incidence of
venous thrombosis was much lower, and was similar to the
reported incidence of bleeding during anticoagulant treat-
ment [17]. Decisions about prophylactic anticoagulant treat-
ment might well be guided by additional risk factors for
venous thrombosis, i.e., surgery or chemotherapy treatment.
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